3 ms·
I remember there was a great post a few weeks back about double-blind controlled trials being used in neonatal care, and the difficulty in getting the medical c
by zaroth 12y ago
I remember there was a great post a few weeks back about double-blind controlled trials being used in neonatal care, and the difficulty in getting the medical community to accept double-blind randomized trials over the last several decades. So I don't want to discount the validity of the method. [1]
But just to belabor the point, couldn't you detect the impact on A1C or a dropping dosage pretty quickly? Everything's logged on the meter/pump/CGM, so you would have an extensive baseline to compare to....
Oh I just realized they want to test this on newly diagnosed patients. Hmmm, in that case I can see more the need for this. I wonder how much the "honeymoon" period would confound the results -- with my son we saw vast changes in required dosages throughout the first year. Not to mention it takes a while to get a handle on how to deal with it, and in the meantime... errors in handling, dosing, mis-counting carbs, etc... combined with honeymooning, I don't know how you could make heads or tails of a newly diagnosed T1D's numbers in just one year, unless the result is very significant.
I wonder why they don't test on people with well controlled T1D. I hope it doesn't imply it's something like AAT where it only possibly works if started soon after onset. I guess it's reasonable to expect early treatment after onset could be more effective, so maybe that figures into their strategy.
[1] - https://news.ycombinator.com/item?id=8490442 https://news.ycombinator.com/item?id=8490442
- cperciva 12y agoThey're doing this on newly diagnosed patients because that's where they hope to see results: This isn't expected to be a cure so much as a "honeymoon extension" solution -- they're looking at preventing further beta cell destruction, not creating new beta cells.